The overall ratings of 7 Pharmaceuticals stocks are down on Portfolio Grader this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This is a rough week for Novartis AG Sponsored ADR (NVS). The company’s rating falls to F from the previous week’s D. Novartis AG Sponsored ADR manufactures pharmaceutical and consumer healthcare products. For more information, get Portfolio Grader’s complete analysis of NVS stock.

Pfizer Inc. (PFE) slips from a C to a D this week. Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. For more information, get Portfolio Grader’s complete analysis of PFE stock.

This week, Lannett Company, Inc.’s (LCI) rating worsens to a F from the company’s D rating a week ago. Lannett Company, Inc. manufactures and distributes pharmaceutical products under its own trade name and under generic names. For more information, get Portfolio Grader’s complete analysis of LCI stock.

Relypsa, Inc. (RLYP) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of RLYP stock.

Cynapsus Therapeutics Inc. (CYNA) declines this week from a C to a D. The company also gets F’s in earnings revisions, earnings surprise, and return on equity. For more information, get Portfolio Grader’s complete analysis of CYNA stock.

This week, Assembly Biosciences, Inc. (ASMB) drops from a C to a D rating. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ASMB stock.

NovaBay Pharmaceuticals, Inc. (NBY) gets weaker ratings this week as last week’s D drops to a F. NovaBay Pharmaceuticals, Inc. develops product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of NBY stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.